Located in Edinburgh BioQuarter, ImmunoSolv is an R&D biotechnology company that specialises in antibody-based strategies for detection and manipulation of dead and dying cells. If they persist, such cells are detrimental to their viable neighbours and are rapidly removed from tissues in the body by efficient clearance mechanisms. We have developed novel clearance technology that recapitulates this process in the laboratory, thus allowing improved viability and quality of cells for research, biomanufacturing and therapy. We are also applying our core antibody technology to target cells undergoing programmed cell death (apoptosis) and the products of apoptotic cells in order to develop novel anti-cancer therapeutics.

  
   
 

 

 

 
 
 
 

 
 

Founded on world class science from the University of Edinburgh Centre for Inflammation Research in 2005 by Professor Christopher Gregory, Dr Ruth Murray and Dr John Pound, ImmunoSolv is a spin-out of the University of Edinburgh College of Medicine and Veterinary Medicine. The company was founded on work established in Professor Gregory’s research laboratories at the University with the aid of significant funding from the Scottish Enterprise Proof-of-Concept Scheme.

Our  activities are focused on:

  1. Development of R&D antibody-based products for detection and depletion of dead and dying cells. Click for more information on our current range of Dead-Cert® products.
  2. Development of products for improving bioprocessing and supply of therapeutic cells and proteins through dead-cell removal.
  3. Development of novel anti-cancer therapeutics aimed at switching host immune responses to apoptotic tumour cells which are present at high frequency in high-grade malignancies.
 
 

Ruth Murray, PhD. Co-founder and Chief Executive Officer

After a PhD at the University of Birmingham, Ruth worked  as a research scientist in virology, immunology and cancer research for seven years.Ruth studied law and qualified as a solicitor in 1996. She then worked for major commercial legal firms in England, and latterly in Edinburgh, where she gained considerable experience in commercial and intellectual property law. Together with Chris Gregory, Ruth formed Immunosolv Limited. She left commercial law practice to become Immunosolv’s first employee in April 2007, when the company won a SMART award. Research carried out since then has resulted in intellectual property forming the basis of several patent applications and the first of the company’s portfolio of products to be launched for sale.

Christopher Gregory, PhD. Co-founder and Chief Scientific Officer

Chris Gregory is Professor of Inflammatory Cell Biology and Deputy Director of the MRC Centre for Inflammation Research, University of Edinburgh, Scotland. He leads the Inflammation and Cancer Group in the Centre. His interests are in the role of inflammatory processes in tumourigenesis and anti-tumour immunity. He has particular interests in the regulation of apoptosis in tumours, especially non-Hodgkin lymphomas, the mechanisms underlying the interaction of apoptotic tumour cells with tumour-associated macrophages, the consequences of such interactions for anti-tumour immunity and the manipulation of these mechanisms for therapeutic gain. He has more than 25 years’ experience of researching and teaching cellular immune mechanisms, especially the regulation of apoptosis in the context of B-cell neoplasia and also has significant experience of commercialisation of academic research and company formation.

Andy J. R. Porter, FRSE

Andy Porter is Professor of Biotechnology and Deputy Director of the Institute of Medical Sciences, University of Aberdeen.  He was founder and CSO of Haptogen Ltd, acquired by Wyeth Inc in October 2007.  In 2005 he was made the Ernst and Young Plc, Science and Technology Entrepreneur of the Year.  He has been a Fellow of the Royal Society of Edinburgh since 2006.
Andy sits on the Executive Committee of Biotechnology Industry Association Scotland, the Life Science Alliance Executive Committee and more recently the Scottish parliament's Science Advisory Committee.  He also has a number of non-executive Board positions within the Scottish biotechnology sector, and has established a small venture fund investing in early stage Scottish immuno-biotechnology companies.

ImmunoSolv Limited is a company incorporated in Scotland with registered company number SC291764 and having its registered office at Quartermile One, 15 Lauriston Place, Edinburgh EH3 9EP, UK